Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.33 |
| ▸ | NEU2 | Q9Y3R4 | 3/20 | 0.33 |
| ▸ | NEU4 | Q8WWR8 | 2/20 | 0.33 |
| ▸ | NEU3 | Q9UQ49 | 2/20 | 0.33 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.33 |
| ▸ | MAG | P20916 | 2/20 | 0.33 |
| ▸ | SELL | P14151 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17117576 | 1.00 | NANP (0.52) | NANPL3MBTL1ASGR1NEU2NEU4 | |
| SCHEMBL15746561 | 1.00 | NANP (0.52) | NANPL3MBTL1ASGR1NEU2NEU4 | |
| SCHEMBL27391399 | 1.00 | NANP (0.52) | NANPL3MBTL1ASGR1NEU2NEU4 | |
| SCHEMBL18231344 | 0.88 | L3MBTL1 (0.42) | NANPL3MBTL1ASGR1NEU2NEU4 | |
| SCHEMBL24246810 | 0.88 | NANP (0.41) | NANPL3MBTL1ASGR1MAGALDH1A1 | |
| SCHEMBL27391404 | 0.88 | NANP (0.41) | NANPL3MBTL1ASGR1MAGALDH1A1 | |
| SCHEMBL25576480 | 0.88 | NANP (0.41) | NANPL3MBTL1ASGR1MAGALDH1A1 | |
| SCHEMBL21016580 | 0.88 | L3MBTL1 (0.41) | NANPL3MBTL1NEU3MAG | |
| SCHEMBL18495194 | 0.86 | L3MBTL1 (0.40) | NANPL3MBTL1 | |
| SCHEMBL16174059 | 0.85 | NANP (0.40) | NANPL3MBTL1ASGR1NEU2NEU4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10342812-B2 | Glycan-based drugs, therapies and biomarkers | B&H BIOTECHNOLOGIES, LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-20140294867-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING | GENZYME CORPORATION (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294867-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING | CD2BP2, SIGLEC7, B3GAT3 | NANP 315/4885L3MBTL1 1928/4885ASGR1 18/4885 |
| US-10342812-B2 | Glycan-based drugs, therapies and biomarkers | FUT6, UGGT1, CSGALNACT1 | NANP 94/4885L3MBTL1 1611/4885ASGR1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.